Minimal Residual Disease MRD Monitoring for BCLL Test
Introduction
The Minimal Residual Disease (MRD) Monitoring for B-cell Chronic Lymphocytic Leukemia (BCLL) Test is an essential diagnostic tool used in the management of leukemia. This test plays a significant role in evaluating the effectiveness of treatment and monitoring disease progression or recurrence. By detecting small numbers of cancer cells that may remain after treatment, healthcare providers can make informed decisions regarding patient care and necessary interventions.
What the Test Measures
This test specifically measures the presence of residual leukemia cells in the bone marrow and blood, which is vital for understanding the patient’s response to therapy. It utilizes advanced flow cytometry techniques to identify and quantify these cells, providing a clear picture of the patient’s hematological status.
Who Should Consider This Test?
Patients diagnosed with B-cell Chronic Lymphocytic Leukemia (BCLL) should consider this test, especially if they exhibit symptoms such as:
- Fatigue
- Unexplained weight loss
- Frequent infections
- Swollen lymph nodes
Additionally, individuals with risk factors like a family history of leukemia or prior treatment for BCLL should also discuss MRD monitoring with their healthcare provider.
Benefits of Taking the Test
- Early detection of disease recurrence
- Assessment of treatment effectiveness
- Guidance for future treatment decisions
- Enhanced patient management and care
Understanding Your Results
Results from the MRD test will help your healthcare provider understand the current state of your disease. A negative result indicates no residual disease, while a positive result may necessitate further treatment or monitoring. Always consult your hematologist or oncologist for a detailed interpretation of your results.
Test Pricing
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Minimal Residual Disease MRD Monitoring for BCLL Test | KSh 34,000 | KSh 50,000 |
Sample Collection and Instructions
For this test, a sample of 3 mL (1 mL min.) bone marrow (first pull aspirate) in a green top (sodium heparin) tube and 4 mL (3 mL min.) whole blood in two green top (sodium heparin) tubes is required. Samples must be mixed thoroughly and shipped immediately at a temperature of 18°C to 22°C or 2°C to 8°C. DO NOT FREEZE. The following information is mandatory:
- Sample time point (chemotherapy time points)
- Previous diagnostic immunophenotype report
- Clinical history and original test request form (TRF)
- Date and time when the sample was drawn
- Therapy details
- 2 or 3 unstained BMA smears or peripheral smears to be made at the source
Book Your Test Today!
We have branches across all major cities in Kenya, making it easy for you to access our services. To book the Minimal Residual Disease MRD Monitoring for BCLL Test, please call or WhatsApp us at +254711564616. Ensure your health is monitored accurately with our reliable testing services.
